)
Visual
test
Sutro Biopharma
Sutro Biopharma (STRO) investor relations material
Sutro Biopharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Mar, 2026
Executive summary
Completed dosing of three cohorts in Phase 1 trial of STRO-004, with initial clinical data expected mid-2026.
Advanced STRO-006 toward clinical development and accelerated STRO-227 IND submission to 2026.
Initiated patient dosing in Astellas-partnered dual-payload iADC program, triggering milestone payments.
Strengthened cash position with $110M capital raise, extending runway into at least Q2 2028.
Financial highlights
Revenue for 2025 was $102.5M, up from $62.0M in 2024, mainly from Astellas and Ipsen collaborations.
R&D and G&A expenses totaled $207.4M in 2025, down from $300.5M in 2024.
Net loss for 2025 was $191.1M, compared to $225.1M in 2024.
Cash, cash equivalents, and marketable securities were $141.4M as of Dec 31, 2025, excluding $110M from recent financing.
Outlook and guidance
Initial clinical data for STRO-004 expected mid-2026; STRO-006 to enter clinical development in 2026.
IND submission for STRO-227 targeted for 2026.
Cash runway projected into at least Q2 2028, excluding future milestones.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sutro Biopharma
- Next-generation ADCs advance toward key milestones, targeting major oncology markets with strong data.STRO
Corporate presentation24 Mar 2026 - Up to $300M in securities registered, including $100M ATM equity via TD Cowen for broad corporate use.STRORegistration filing23 Mar 2026
- Accelerated ADC pipeline advances with key clinical data and INDs expected in the next year.STROThe Citizens Life Sciences Conference 202610 Mar 2026
- Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year.STROTD Cowen 46th Annual Health Care Conference4 Mar 2026
- Accelerated ADC pipeline and platform innovation drive clinical progress and strategic growth.STRO44th Annual J.P. Morgan Healthcare Conference3 Feb 2026
- Luvelta's pivotal trials and platform innovation target broader patient access and industry leadership.STRO2024 Wells Fargo Healthcare Conference22 Jan 2026
- Three INDs and registrational trials highlight strong ADC pipeline and financial strength.STROStatus Update19 Jan 2026
- Next-gen ADC platform advances three lead oncology programs with strong preclinical and clinical momentum.STROCorporate presentation15 Jan 2026
- Luvelta advances in pivotal trials as next-gen ADC pipeline and strong funding drive growth.STROJefferies London Healthcare Conference 202412 Jan 2026
Next Sutro Biopharma earnings date
Q1 20267 May, 2026
Sutro Biopharma
Next Sutro Biopharma earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage